Oct 022023
Drug Name |
Active Ingredient(s) |
Approval Date |
FDA-Approved Use on Approval Date |
Press Release |
Drug Trials Snapshot |
| Rivfloza | nedosiran | 9/29/2023 | To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney function | Drug Trials Snapshot | |
| Pombiliti | cipaglucosidase alfa-atga | 9/28/2023 | To treat late-onset Pompe disease | Drug Trials Snapshot | |
| Exxua | gepirone | 9/22/2023 | To treat major depressive disorder | ||
| Ojjaara | momelotinib | 9/15/2023 | To treat intermediate or high-risk myelofibrosis in adults with anemia | ||
| Aphexda | motixafortide | 9/8/2023 | To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma | Drug Trials Snapshot |
Sorry, the comment form is closed at this time.